CME
How Does RWE Expand Understanding of CDK4/6 Inhibitor Use in Special Populations With HR+/HER2- Metastatic Breast Cancer?
February 10, 2023
Guest: Adam M. Brufsky, MD, PhD The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastati
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!